2-(Fluoromethyl)pyrrolidine hydrochloride | 1781050-17-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-(Fluoromethyl)pyrrolidine hydrochloride
• 英文别名: 2-(fluoromethyl)pyrrolidine;hydrochloride
• CAS: 1781050-17-6
• 化学式: C₅H₁₀FN*ClH
• 分子量: 139.6
• InChiKey: AUADADXQUIBHDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.13
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(Fluoromethyl)pyrrolidine hydrochloride 、 苯甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以47 %的产率得到(2-(fluoromethyl)pyrrolidin-1-yl)(phenyl)methanone
  参考文献：
  名称：

  氟烷基取代基对饱和杂环胺理化性质的影响

  摘要：

  用它们的氟烷基取代的类似物替代氮杂环丁烷、吡咯烷和哌啶显示出调节碱性、亲脂性和水溶性。对获得的理化数据进行综合分析，以指导合理微调与药物优化相关的化合物性质。

  DOI：

  10.1002/chem.202201601

文献信息

• Substituted Imidazopyridines as HDM2 Inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140179680A1

  公开（公告）日：2014-06-26

  The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

  本发明提供了如本文所述的取代咪唑吡啶或其药用可接受的盐或溶剂。代表性化合物可用作HDM2蛋白的抑制剂。还公开了包括上述化合物的药物组合物以及使用它们治疗癌症的潜在方法。
• [EN] 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS<br/>[FR] PURINES 2,6,7,8-SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE HDM2
  申请人：MERCK SHARP & DOHME

  公开号：WO2014120748A1

  公开（公告）日：2014-08-07

  The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

  本发明提供如本文所述的2,6,7,8取代嘌呤或其药学上可接受的盐。代表性化合物可用作HDM2蛋白的抑制剂。还公开了包括上述化合物的药物组合物以及使用它们治疗癌症的潜在方法。
• Pyridone derivative
  申请人：Otake Norikazu

  公开号：US20070208046A1

  公开（公告）日：2007-09-06

  The invention provides pyridone derivatives represented by a general formula (I) [in the formula, R 1 and R 2 may be same or different and stands for H, etc., or R 1 and R 2 may form an aliphatic nitrogen-containing heterocyclic group together with the N to which they bind; X 1 -X 3 may be same or different and stand for methine or N, provided not all of them simultaneously stand for nitrogen; X 4 -X 7 may be same or different and stand for methine or N, provided that three or more of them do not simultaneously stand for N; Y 1 and Y 3 may be same or different and stand for single bond, —O—, —NR—, —S—, etc; Y 2 stands for lower alkylene, etc.; R stands for H, etc., L stands for methylene; Z 1 and Z 2 may be same or different and stand for single bond or lower alkylene; or R 1 , L and Z 2 may form an aliphatic nitrogen-containing heterocyclic group with the N to which R 1 binds; and Ar stands for aromatic carbocyclic group, etc.].

  该发明提供了由通式（I）表示的吡啶酮衍生物[在公式中，R1和R2可能相同或不同，代表H等，或者R1和R2可能与它们结合的N一起形成一个脂肪族含氮杂环基团；X1-X3可能相同或不同，代表亚甲或N，但不能同时都代表氮；X4-X7可能相同或不同，代表亚甲或N，但不能同时有三个或更多同时代表N；Y1和Y3可能相同或不同，代表单键，-O-，-NR-，-S-等；Y2代表较低的烷基等；R代表H等，L代表亚甲基；Z1和Z2可能相同或不同，代表单键或较低的烷基；或者R1、L和Z2可能与R1结合的N一起形成一个脂肪族含氮杂环基团；Ar代表芳香族碳环基团等]。
• FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
  申请人：SERAGON PHARMACEUTICALS, INC

  公开号：US20150005286A1

  公开（公告）日：2015-01-01

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了一些雌激素受体调节剂化合物。还描述了包括上述化合物的药物组成物和药物，以及使用这种雌激素受体调节剂的方法，单独或与其他化合物联合治疗介导或依赖于雌激素受体的疾病或病症。
• SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140357618A1

  公开（公告）日：2014-12-04

  The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

  本发明提供了如本文所述的取代咪唑吡啶或其药学上可接受的盐或溶剂。代表性化合物可用作HDM2蛋白的抑制剂。还公开了包含上述化合物的药物组合物以及使用它们治疗癌症的潜在方法。